Cytori Therapeutics (CYTX) Expands European Celution System Approval to Other Indications
Cytori Therapeutics Inc. is a biopharmaceutical company developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Data suggests ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. The company announced today that it has expanded the Celution System CE Mark approval in Europe to include several new indications including cryptoglandular fistula. This is the most common cause of perianal infection, abnormal fecal contamination and incontinence. This new indication will facilitate the use of the Celution System for clinical cases potentially as part of…